Corticosteroids decrease COVID-19 vaccine efficacy in IBD

Though there is no significant difference in COVID-19 infection rates among patients with inflammatory bowel disease compared with the general public, some IBD therapies correlated with increased infection severity.“The therapies for IBD are predominantly immune-based, immune modifying and sometimes immune suppressive,” David T. Rubin, MD, FACG, University of Chicago, said at the ACG Virtual Grand Rounds 2021. “There’s been increased concern and fear that the therapies for IBD are increasing the risk for severe COVID-19 outcomes or might affect the response to vaccinations.Read More

Share on facebook
Share on twitter
Share on linkedin